Calprotectin as a valuable prognostic marker in care of COVID-19 patients
The rising numbers of SARS-CoV-2 infections during the recent weeks are again pushing the health systems to their limits. Early identification of infected patients who will develop severe COVID-19 can help hospitals to better allocate essential resources.
The role of calprotectin (plasma and serum) in early identification of neutrophil activation and hyper-inflammatory response in both COVID-19 and COVID-19 related sepsis has been confirmed in several studies. These research results indicate that calprotectin can be used in the risk assessment and prediction of which COVID-19 patients are at risk of developing severe complications such as respiratory failure and/or mortality.
Therefore, calprotectin can be used as a valuable biomarker for early evaluation of the disease severity and identification of patients at risk to progress to severe form of the disease, contributing to effective triage and care of COVID-19 patients.
Below you will find more information about plasma and serum calprotectin related to COVID-19. If you are interested in more information about calprotectin or in validation at your laboratory, please reach out to marketing@gentian.com
WEBINAR: The role of calprotectin in COVID-19
ARTICLES AND STUDIES

Contact us for further information
GCAL® is an immunoassay applied to turbidimetry-based clinical chemistry platforms. It is an open channel assay, meaning it can be added to all clinical chemistry analysers.
- CE-marked since 2017
- IVDR registration in progress
- Developed and manufactured by Gentian
- Manufactured according to ISO 13485:2016
Explore GCAL® in your laboratory - fill out the form or send an email to marketing@gentian.com for more information about the product and prices.
